Zhejiang, China

Yaxin Liang


Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yaxin Liang: Innovator in Anti-Inflammatory Peptides

Introduction

Yaxin Liang is a notable inventor based in Zhejiang, China. He has made significant contributions to the field of active peptides, particularly focusing on anti-inflammatory applications derived from egg white protein. His innovative work has the potential to impact various health-related industries.

Latest Patents

Yaxin Liang holds a patent for an "Egg white protein anti-inflammatory peptide and application thereof." This patent relates to the technical field of active peptides and specifically addresses the preparation and application of a Maillard reaction product. The anti-inflammatory peptide identified in his research is FGPH. At a concentration of 500 μg/mL, this peptide demonstrates inhibition ratios of 64.41±0.47% for nitric oxide (NO) and varying inhibition rates for inflammatory factors such as TNF-alpha, IL-6, and IL-1 beta.

Career Highlights

Throughout his career, Yaxin Liang has worked with reputable organizations, including Hangzhou Bibau Biotechnology Co., Ltd. and Beijing Forestry University. His experience in these institutions has allowed him to develop and refine his expertise in peptide research and applications.

Collaborations

Yaxin Liang has collaborated with several professionals in his field, including Aqin Wang and Difeng Ren. These partnerships have contributed to the advancement of his research and the successful development of his patented innovations.

Conclusion

Yaxin Liang's work in the development of anti-inflammatory peptides showcases his innovative spirit and dedication to advancing health-related technologies. His contributions are poised to make a significant impact in the field of active peptides.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…